3.0
6. Sept. 2015
Mitarbeiter (anonym)
Aktueller Mitarbeiter, mehr als 10 Jahre
South San Francisco, CA
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
"Patients first" and "science driven" are not just slogans, they are meaningful and motivating.
Kontras
The ability to get things done has greatly eroded. Politics within and across functions have removed projects as the central focus. There are too many committees before decisions are made, which slows everything in the pipeline and portfolio. Leadership is average, used to be stellar. Is now an extremely risk averse environment, after Roche acquired Genentech. Benefits chiseled away every year. Even the price of food in cafeteria has risen - salmon, rice, carrots this week for lunch was over $10.